Close Menu

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

The Phase I/II trial of PC14586 will involve patients with advanced solid tumors characterized by the p53 Y220C mutation.

Through the partnership, Newsoara will develop and commercialize up to six targeted agents in greater China, while AUM will retain rights to the agents.

The trial is evaluating BP1002 to treat lymphoma and chronic lymphocytic leukemia patients whose tumors overexpress the protein BCL-2.

As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.

The UK-based firm will use the funds to advance its bespoke neoantigen-targeting T-cell therapies for solid cancers including melanoma and NSCLC.